Login to Your Account



Analyst: "Worst Case Scenario"

Alimera and Psivida Sink As Iluvien Rejected Again

By Trista Morrison
BioWorld Insight Editor

Monday, November 14, 2011

Shares of Alimera Sciences Inc. and partner pSivida Corp. plunged Friday afternoon in the wake of a second complete response letter for diabetic macular edema drug Iluvien (fluocinolone acetonide intravitreal insert).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription